Advertisement

Erlotinib

  • Martin Steins
  • Michael Thomas
  • Michael Geißler
Chapter
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 211)

Abstract

The epidermal growth factor receptor (EGFR) has been implicated in a multiplicity of cancer-related signal transduction pathways like cellular proliferation, adhesion, migration, neoangiogenesis and apoptosis inhibition, all of which are important features of cancerogenesis and tumour progression. Its tyrosine kinase activity plays a central role in mediating these processes and has been intensely studied to exploit it as a therapeutic target. Inhibitors of this pathway have been developed and assessed in trials with significant efficacy in clinical applications. The current review focuses in particular on the clinical data of EGFR tyrosine kinase inhibition in different tumour entities, preferably non-small cell lung cancer and pancreatic cancer with emphasis to the approved small molecule erlotinib. Its clinical applications, evidence-based efficacy and toxicity as well as predictive markers of response are discussed.

Keywords

Epidermal growth factor receptor Erlotinib Tyrosine kinase inhibitor 

References

  1. Alroy I, Yarden Y (1997) The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 410:83–86CrossRefPubMedGoogle Scholar
  2. Bezjak A, Tu D, Seymour L et al (2006) Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study Br. 21. J Clin Oncol 24:3831–3837CrossRefPubMedGoogle Scholar
  3. Birk D, Gansauge F, Gansauge S (1999) Serum and correspondent tissue measurements of epidermal growth factor (EGF) and epidermal growth factor receptor (EGF-R). Clinical relevance in pancreatic cancer and chronic pancreatitis. Int J Pancreatol 25:89–96CrossRefPubMedGoogle Scholar
  4. Boeck S, Hausmann A, Reibke R et al (2007) Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. Anticancer Drugs 18:1109–1111CrossRefPubMedGoogle Scholar
  5. Brabender J, Danenberg KD, Metzger R et al (2001) Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 7:1850–1855PubMedGoogle Scholar
  6. Bramhall SR, Schulz J, Nemunaitis J (2002) A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87:161–167CrossRefPubMedPubMedCentralGoogle Scholar
  7. Buckley AF, Burgart LJ, Sahai V et al (2008) Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am J Clin Pathol 129:245–251CrossRefPubMedGoogle Scholar
  8. Burris HA 3rd, Moore MJ, Andersen J (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413CrossRefPubMedGoogle Scholar
  9. Cedrés S, Prat A, Martínez P et al (2009) Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib. Lung Cancer 66:257–261CrossRefPubMedGoogle Scholar
  10. Chen G, Fen J, Zhou C et al (2013) Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR-mutation positive non-small cell lung cancer (NSCLC). Ann Oncol 24:1615–1622CrossRefPubMedGoogle Scholar
  11. Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34CrossRefPubMedGoogle Scholar
  12. Chiang D, Villanueva A, Peix J (2008) Focal VEGFA amplifications and molecular classification of hepatocellular carcinoma. Cancer Res 68:6779–6788CrossRefPubMedPubMedCentralGoogle Scholar
  13. Crinó L, Cappuzzo F, Zatloukal P et al (2008) Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol 26:4253–4260CrossRefPubMedGoogle Scholar
  14. Dudek AZ, Kmak KL, Koopmeiners J, Keshtgarpour M (2006) Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. Lung Cancer 51:89–96CrossRefPubMedGoogle Scholar
  15. Duffy A, Kortmansky J, Schwartz GK et al (2008) A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Ann Oncol 19:86–91CrossRefPubMedGoogle Scholar
  16. El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745–750CrossRefPubMedGoogle Scholar
  17. Epelbaum R, Schnaider J, Gluzman A (2007) Erlotinib as a single-agent therapy in patients with advanced pancreatic cancer. In: ASCO gastrointestinal cancer symposium, Orlando, FL, 19–21 Jan 2007Google Scholar
  18. Fukuoka M, Wu YL, Thongprasert S et al (2011) Biomarker analyses and final overall survival results from a phase III randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small cell lung cancer in Asia (IPASS). J Clin Oncol 29:2866–2874CrossRefPubMedGoogle Scholar
  19. Fukuoka M, Yano S, Giaccone G et al (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237–2246CrossRefPubMedGoogle Scholar
  20. Gao JW, Zhan P, Qiu XY, Jin JJ et al (2017) Erlotinib-based doublet targeted therapy versus erlotinib alone in previously treated advanced non-small-cell lung cancer: a meta-analysis from 24 randomized controlled trials. Oncotargets 8:73258–73270Google Scholar
  21. Garassino MC, Martelli O, Broggini M et al (2013) Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 14:981–988Google Scholar
  22. Garon EB, Reck M, Paz-Ares L et al (2017) Treatment rationale and study design for the RELAY study: a multicenter, randomized, double-blind study of erlotinib with ramucirumab or placebo in patients with epidermal growth factor receptor mutation-positive metastatic non-small-cell lung cancer. Clin Lung Cancer 18:96–99CrossRefPubMedGoogle Scholar
  23. Gatzemeier U, Pluzanska A, Szczesna A et al (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva lung cancer investigation trial. J Clin Oncol 25:1545–1552CrossRefPubMedGoogle Scholar
  24. Giaccone G, Herbst RS, Manegold C et al (2004) Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol 22:777–784Google Scholar
  25. Herbst RS, Prager D, Hermann R et al (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892–5899CrossRefPubMedGoogle Scholar
  26. Huether A, Hopfner M, Sutter AP et al (2006) Signaling pathways involved in the inhibition of epidermal growth factor receptor by erlotinib in hepatocellular cancer. World J Gastroenterol 12:5160–5167PubMedPubMedCentralGoogle Scholar
  27. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341–354CrossRefGoogle Scholar
  28. Iannitti D, Dipetrillo T, Akerman P (2005) Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. Am J Clin Oncol 28:570–575CrossRefPubMedGoogle Scholar
  29. Kato T, Seto T, Nishio M et al (2017) Erlotinib plus bevacizumab phase II study in patients with advanced non-small-cell lung cancer (JO25567): updated safety results. Drug Saf 41:229–237Google Scholar
  30. Kim ES, Hirsh V, Mok T et al (2008) Gefitinib versus docetaxel in previously treated non-small cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372:1809–1818CrossRefPubMedGoogle Scholar
  31. Kindler H, Niedzwiecki D, Hollis D et al (2010) Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28:3617–3622CrossRefPubMedPubMedCentralGoogle Scholar
  32. Kris MG, Natale RB, Herbst RS et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149–2158CrossRefPubMedGoogle Scholar
  33. Kulke MH, Blaszkowsky LS, Ryan DP et al (2007) Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 25:4787–4792CrossRefPubMedGoogle Scholar
  34. Llovet JM, Brú C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338CrossRefPubMedGoogle Scholar
  35. Llovet JM, Bruix J (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48:1312–1327CrossRefPubMedPubMedCentralGoogle Scholar
  36. Llovet JM, Ricci S, Mazzaferro V et al, SHARP Investigators Study Group (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390Google Scholar
  37. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139CrossRefPubMedGoogle Scholar
  38. Lynch TJ Jr, Kim ES, Eaby B (2007) Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 12:610–621CrossRefPubMedGoogle Scholar
  39. Marchetti A, Martella C, Felicioni L et al (2005) EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23:857–865CrossRefPubMedGoogle Scholar
  40. Mok T, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957CrossRefPubMedGoogle Scholar
  41. Moore MJ, Goldstein D, Hamm J (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966CrossRefPubMedGoogle Scholar
  42. Moore MJ, Hamm J, Dancey J (2003) Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY12–9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21:3296–3302CrossRefPubMedGoogle Scholar
  43. Natale RB (2004) Effects of ZD1839 (Iressa, gefitinib) treatment on symptoms and quality of life in patients with advanced non-small cell lung cancer. Sem Oncol 31(3 suppl 9):23–30CrossRefGoogle Scholar
  44. Neuhaus P, Riess H, Post S et al (2008) CONKO-001: final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). J Clin Oncol 26:abstr LBA4504Google Scholar
  45. Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37(suppl 4):S9–S15CrossRefPubMedGoogle Scholar
  46. Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500CrossRefPubMedGoogle Scholar
  47. Parkin DM, Bray F, Ferlay J (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108CrossRefPubMedGoogle Scholar
  48. Pao W, Miller V, Zakowski M et al (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306–13311CrossRefPubMedGoogle Scholar
  49. Pao W, Miller VA (2005) Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small cell lung cancer: current knowledge and future directions. J Clin Oncol 23:2556–2568CrossRefPubMedGoogle Scholar
  50. Pelzer U, Kubica K, Stieler J et al (2008) A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 26 (suppl): abstr 4508Google Scholar
  51. Pérez-Soler R, Chachoua A, Hammond LA et al (2004) Determants of tumour response and survival with erlotinib in patients with non-small-cell lung cancer: a randomized trial. J Clin Oncol 22:3238–3247CrossRefPubMedGoogle Scholar
  52. Pérez-Soler R (2006) Rash as a surrogate marker for efficacy of epidermal growth factor inhibitors in lung cancer. Clin Lung Cancer 8(suppl 1):S7–14CrossRefPubMedGoogle Scholar
  53. Philip PA, Benedetti J, Fenoglio-Preiser C (2007) Phase III study of gemcitabine (G) plus cetuximab (C) versus gemcitabine in patients (Pts) with locally advanced or metastatic pancreatic adenocarcinoma (PC) SWOG S0205 study. J Clin Oncol 25(suppl 18): LBA4509Google Scholar
  54. Philip PA, Mahoney MR, Allmer C (2005) Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 23:6657–6663CrossRefPubMedGoogle Scholar
  55. Ramalingam SS, Yang JC, Lee CK et al (2017) Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. J Clin Oncol 36:841–849Google Scholar
  56. Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239–246CrossRefPubMedGoogle Scholar
  57. Schneider G, Hamacher R, Eser S et al (2008) Molecular biology of pancreatic cancer—new aspects and targets. Anticancer Res 28(3A):1541–1550PubMedGoogle Scholar
  58. Saif MW, Merikas I, Tsimboukis S et al (2008) Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients. JOP 9:267–274PubMedGoogle Scholar
  59. Salomon DS, Brandt R, Ciardiello F et al (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183–232CrossRefPubMedGoogle Scholar
  60. Sandler AB (2006) Nondermatologic adverse events associated with anti-EGFR therapy. Oncology 20(5 Suppl 2):35–40PubMedGoogle Scholar
  61. Seto T, Kato T, Nishio M et al (2014) Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol 15:1236–1244CrossRefPubMedGoogle Scholar
  62. Shapiro J, Marshall J, Karasek P (2005) G17DT + gemcitabine (Gem) versus placebo + Gem in untreated subjects with locally advanced, recurrent, or metastatic adenocarcinoma of the pancreas: results of a randomized, double-blind, multinational, multicenter study. J Clin Oncol 23(suppl 16):4012CrossRefGoogle Scholar
  63. Shepherd FA, Pereira JR, Ciuleanu T et al for the National Cancer Institute of Canada Clinical Trails Group (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132Google Scholar
  64. Soria JC, Felip E, Cobo M et al (2015) Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol 16:897–907CrossRefPubMedGoogle Scholar
  65. Sultana A, Smith CT, Cunningham D et al (2007) Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 20:2607–2615CrossRefGoogle Scholar
  66. Tang PA, Tsao MS, Moore MJ (2006) A review of erlotinib and its clinical use. Expert Opin Pharmacother 7:177–193CrossRefPubMedGoogle Scholar
  67. Thomas MB, Chadha R, Glover K (2007) Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 110:1059–1067CrossRefPubMedGoogle Scholar
  68. Thomas MB, Morris JS, Chadha R et al (2009) Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 27:843–850CrossRefPubMedGoogle Scholar
  69. Thongprasert S, Duffield E, Saijo N et al (2011) Health-related quality-of-life in a randomized first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). J Thorac Oncol 6:1872–1880CrossRefPubMedGoogle Scholar
  70. Tsao MS, Sakurada A, Cutz JC et al (2005) Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med 353:133–144CrossRefPubMedGoogle Scholar
  71. Van Cutsem E, Van de Velde H, Karasek P (2004) Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:1430–1438CrossRefPubMedGoogle Scholar
  72. Van Cutsem E, Vervenne WL, Bennouna J et al (2009) Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: results from the AViTA study. In: ASCO gastrointestinal cancers symposium, A117Google Scholar
  73. Villanueva A, Newell P, Chiang D (2007) Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 27:55–76CrossRefPubMedGoogle Scholar
  74. Wacker B, Nagrani T, Weinberg J et al (2007) Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 13:3913–3921CrossRefPubMedGoogle Scholar
  75. Yang JC, Ahn MJ, Kim DW et al (2017) Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component. J Clin Oncol 35:1288–1296CrossRefPubMedGoogle Scholar
  76. Xiong HQ, Abbruzzese JL (2002) Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol 29(14 suppl):31–37CrossRefPubMedGoogle Scholar
  77. Zhou C, Wu YL, Chen G et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomized phase 3 trial. Lancet Oncol 12:735–742CrossRefPubMedGoogle Scholar
  78. Zhu C-Q, da Cunha Santos G, Ding K et al (2008) Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study Br. 21. J Clin Oncol 26:4268–4275CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Clinic for Thoracic DiseasesUniversity of HeidelbergHeidelbergGermany
  2. 2.Department of Oncology, Gastroenterology and Internal MedicineStädtische Kliniken EsslingenEsslingenGermany

Personalised recommendations